Sr Principal - Analyst; Economic Modelling at Eli Lilly and Company

Cork, County Cork, Ireland

Eli Lilly and Company Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, HealthcareIndustries

Requirements

  • Ability to work with cross-functional, multidisciplinary teams
  • Talented, energetic, creative, diverse, influential, and collaborative

Responsibilities

  • Plan, write, edit, review and coordinate the adaptation of Economic Models, model technical reports and HTA documents
  • Conduct quality checks to ensure data accuracy in the economic model
  • Collate the reviewer's comments, revise the economic models and related documents
  • Develop Health Technology Assessment (HTA) related documents (including but not limited to cost-effectiveness analysis model adaptation, preparation or adaptation of economic model technical reports, systematic literature review of economic evaluations, development of a written response to payers regarding economic modelling)
  • Facilitate external scientific publications (including but not limited to abstracts, posters, manuscripts, and presentations)

Skills

Economic Modelling

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI